ArticleAnnals of internal medicine2023

KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD.

Matthew van Norman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.